Pioneers in Science

When AbbVie launched the first fully human monoclonal antibody, we established a foundation and commitment to move science forward to further develop medicines that can change the lives of people with immune-mediated diseases.

Discovery and development capabilities

We've invested in groundbreaking technologies and platforms that aim to deliver better solutions to our patients. These include protein-based technologies that enhance the therapeutic potential of antibodies by combining them with small molecule drugs.

Antibody Drug Conjugates (ADCs)
This technology platform uses the targeting of an antibody to deliver a therapeutic agent. ADC technology is more traditionally used in oncology however, by coupling a highly potent immunomodulator to an anti-inflammatory monoclonal antibody, it can be delivered to dysregulated immune cells with the goal to turn down inflammation,

restore normal immune function and spare normal tissue. By combining AbbVie’s expertise in discovering and developing specific monoclonal antibodies with our experience in small molecule chemistry, AbbVie is leading the field in applying ADC technology to immune-mediated diseases.

Combination therapies
We've also concentrated our efforts on boosting the therapeutic potential of specific small molecule inhibitors by generating combinations of small molecule approaches in fixed dose combinations.

Targeted treatments
Targeted drug delivery is a vital avenue of our research because it can change the fundamental way diseases are treated. We are exploring several new methods for delivering medicines.